November 2003
Worldwide Biotech;Nov2003, Vol. 15 Issue 11, p2
Trade Publication
Reports on the revenue-generating collaborative agreement in inflammatory bowel disease between DanioLabs Ltd. and Oxagen Ltd.


Related Articles

  • Lynx Announces SNP Colaboration With Oxagen.  // Worldwide Biotech;Jul99, Vol. 11 Issue 7, p5 

    Reports that Lynx Therapeutics Inc. signed an agreement with Oxagen Limited regarding a program on the discovery and validation of disease-associated single nucleotide polymorphisms (SNP). Initial focus of the program; Separate tasks of Lynx and Oxagen; Designed uses of Lynx's SNP technologies;...

  • When opportunity knocks. Gopal, Kevin // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p42 

    Reports on James Noble's resignation from British Biotech to become a part-time executive director of Oxagen, the first genomics company in Great Britain. Position held in British Biotech; Career background; Responsibilities as part-time executive director of Oxagen.

  • VASTox On Buying Spree; Next Item: A New Identity. Moran, Nuala // BioWorld International;3/28/2007, Vol. 12 Issue 13, p1 

    The article reports on the acquisitions made by VASTox PLC in London, England. According to the author, the company has simultaneously acquired DanioLabs Ltd. and Dextra Laboratories Ltd., in deals with a total value of £16.5 million. He adds that after these purchases, VASTox intends to...

  • PE Biosystems Signs Agreements.  // Chemical Market Reporter;08/23/99, Vol. 256 Issue 8, p16 

    Reports that PE Biosystems has signed an agreement with Genomica Corporation and Oxagen Ltd. to develop advanced software for genotyping. Significance of the agreement of the three companies; Goal of the collaboration; Supply agreement of PE Biosytems with Sequenom Inc.

  • Oxagen Raises $26M to Boost Midstage Asthma Compound. Moran, Nuala // BioWorld International;11/25/2009, Vol. 14 Issue 47, p1 

    The article reports that Oxagen Ltd. was able to raise 16 million British pounds from a third round of funding, with Novartis Venture Funds as its new investor. Proceeds will be used for the CRTH2 antagonists products of the company to treat inflammatory and respiratory disease. Company chief...

  • Oxagen Spinout Atopix to Advance Allergy Pipeline. Moran, Nuala // BioWorld International;6/5/2013, Vol. 18 Issue 23, p1 

    The article reports on the decision of biopharmaceutical firm Oxagen Ltd. to spin off by creating Atopix Therapeutics Ltd. in order to focus on developing anti-allergy drug OC459. Oxagen gave Atopix the rights to conduct the Phase III clinical study of OC459 and other CRTH2 antagonists for the...

  • Renewed 'Oxagen': $26M Gives More Air for Asthma Compound. Moran, Nuala // BioWorld Today;11/25/2009, Vol. 20 Issue 228, p1 

    The article reports on the announcement of Oxagen Ltd. about the completion of a 16 million pounds worth of third-round funding. The proceeds will be used for the improvement of the company's portfolio of chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTH2)...

  • Oxagen Spinout Atopix to Advance Allergy Pipeline. Moran, Nuala // BioWorld Today;6/6/2013, Vol. 24 Issue 108, p1 

    This article reports that Atopix Therapeutics Ltd., a spin-out of biopharmaceutical firm Oxagen Ltd., will develop the compound OC459 in the treatment of allergic diseases. The product was successful in completing Phase IIb development in asthma, but failed to take funding for a Phase III study...

  • CLINIC ROUNDUP.  // BioWorld Today;12/10/2009, Vol. 20 Issue 237, p7 

    This section offers news briefs concerning clinical trials. Partners Antisoma plc and Novartis Ag are filing for approval of ASA404, a drug for non-small-cell lung cancer. A Phase II trial of BNC105 is being planned by Bionomics Ltd. Oxagen Ltd. has finished enrolling patients for its Phase IIb...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics